Condition: Advanced Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma · Sponsor: Karie Runcie
The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of zanzalintinib (XL092) alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
This description comes directly from the study's public registry record.
Karie Runcie, MD · 212-305-5098 · kr2836@cumc.columbia.edu
Allison Lipps · 317-634-5842 · alipps@hoosiercancer.org
Always discuss trial participation with your own doctor first.
| University of California San Diego | La Jolla, California, United States | Recruiting |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis, Indiana, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06863311